These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28235722)

  • 1. Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes.
    P V J; Nair SV; Kamalasanan K
    Colloids Surf B Biointerfaces; 2017 May; 153():123-131. PubMed ID: 28235722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting.
    Barnard KD; Wysocki T; Thabit H; Evans ML; Amiel S; Heller S; Young A; Hovorka R;
    Diabet Med; 2015 May; 32(5):601-8. PubMed ID: 25615888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of automating insulin delivery for the treatment of type 1 diabetes.
    Steil GM; Rebrin K; Darwin C; Hariri F; Saad MF
    Diabetes; 2006 Dec; 55(12):3344-50. PubMed ID: 17130478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion.
    Zisser H; Dassau E; Lee JJ; Harvey RA; Bevier W; Doyle FJ
    J Diabetes Sci Technol; 2015 May; 9(3):564-72. PubMed ID: 25901023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closed-loop insulin delivery - what lies between where we are and where we are going?
    Steil GM; Rebrin K
    Expert Opin Drug Deliv; 2005 Mar; 2(2):353-62. PubMed ID: 16296759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biotechnological and administration innovations in insulin therapy].
    Verge D
    Med Sci (Paris); 2004 Nov; 20(11):986-98. PubMed ID: 15525494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear.
    Rini CJ; McVey E; Sutter D; Keith S; Kurth HJ; Nosek L; Kapitza C; Rebrin K; Hirsch L; Pettis RJ
    Drug Deliv Transl Res; 2015 Aug; 5(4):332-45. PubMed ID: 26037035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous insulin therapy - end of the road after 80 years?
    Leifke E; Strack TR
    Drugs Today (Barc); 2014 Feb; 50(2):181-201. PubMed ID: 24619592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of insulin delivery devices in diabetes care.
    Garg SK
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S1-3. PubMed ID: 20515296
    [No Abstract]   [Full Text] [Related]  

  • 10. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin pump therapy in adults.
    Didangelos T; Iliadis F
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S109-13. PubMed ID: 21864741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smart approaches to glucose-responsive drug delivery.
    Webber MJ; Anderson DG
    J Drug Target; 2015; 23(7-8):651-5. PubMed ID: 26453161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.
    Ang KH; Sherr JL
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1113-1131. PubMed ID: 28774208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
    Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiology of glucose homeostasis and insulin therapy in type 1 and type 2 diabetes.
    Ferrannini E
    Endocrinol Metab Clin North Am; 2012 Mar; 41(1):25-39. PubMed ID: 22575405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-loop in children with type 1 diabetes: specific challenges.
    Elleri D; Allen JM; Dunger DB; Hovorkea R
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S131-5. PubMed ID: 21864745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic considerations of new insulin formulations and routes of administration.
    Hoffman A; Ziv E
    Clin Pharmacokinet; 1997 Oct; 33(4):285-301. PubMed ID: 9342504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who needs an artificial pancreas? (？).
    Winikoff J; Drexler A
    J Diabetes; 2013 Sep; 5(3):254-7. PubMed ID: 23601378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using technology to advance type 1 diabetes care among women during the reproductive years and in pregnancy.
    Polsky S; Giordano D; Voelmle MK; Garcetti R; Garg SK
    Postgrad Med; 2016 May; 128(4):418-26. PubMed ID: 26924774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.